Amylyx Pharmaceuticals Inc (AMLX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Amylyx Pharmaceuticals Inc stock (AMLX) is currently trading at $13.66. Amylyx Pharmaceuticals Inc PS ratio (Price-to-Sales) is 0.66. Analyst consensus price target for AMLX is $22.80. WallStSmart rates AMLX as Sell.
- AMLX PE ratio analysis and historical PE chart
- AMLX PS ratio (Price-to-Sales) history and trend
- AMLX intrinsic value — DCF, Graham Number, EPV models
- AMLX stock price prediction 2025 2026 2027 2028 2029 2030
- AMLX fair value vs current price
- AMLX insider transactions and insider buying
- Is AMLX undervalued or overvalued?
- Amylyx Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- AMLX Piotroski F-Score and Altman Z-Score
- AMLX analyst price target and Smart Rating
Amylyx Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Amylyx Pharmaceuticals Inc (AMLX) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, institutional own.. Concerns around return on equity and price/book. Significant fundamental concerns warrant caution or avoidance.
Amylyx Pharmaceuticals Inc (AMLX) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
104.47% of shares held by major funds and institutions
Supporting Valuation Data
Amylyx Pharmaceuticals Inc (AMLX) Areas to Watch (4)
Company is destroying shareholder value
Revenue declining -99.60%, a shrinking business
Very expensive at 5.0x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Amylyx Pharmaceuticals Inc (AMLX) Detailed Analysis Report
Overall Assessment
This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 10.0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Institutional Own.. Valuation metrics including Price/Sales (0.66) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Book. Some valuation metrics including Price/Book (5.00) suggest expensive pricing. Growth concerns include Revenue Growth at -99.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -61.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -61.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -99.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
AMLX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
AMLX's Price-to-Sales ratio of 0.66x trades at a deep discount to its historical average of 673.52x (10th percentile). The current valuation is 100% below its historical high of 9633.33x set in Mar 2022, and 32% above its historical low of 0.5x in May 2024. Over the past 12 months, the PS ratio has compressed from ~4.6x as trailing revenue scaled faster than the stock price.
Compare AMLX with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Amylyx Pharmaceuticals Inc (AMLX) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Amylyx Pharmaceuticals Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached -665,000 with 100% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -28M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Amylyx Pharmaceuticals Inc.
Bottom Line
Amylyx Pharmaceuticals Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(36 last 3 months)
| Insider | Type | Shares |
|---|---|---|
MAZZARIELLO, GINA Chief Legal Officer | Sell | -3,419 |
| Insider | Type | Shares |
|---|---|---|
MILNE, GEORGE M JR Director | Sell | -17,780 |
Data sourced from SEC Form 4 filings
Last updated: 8:23:44 AM
About Amylyx Pharmaceuticals Inc(AMLX)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Amylyx Pharmaceuticals Inc (AMLX) is a biopharmaceutical innovator focused on developing groundbreaking therapies for neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). Its flagship candidate, AMX0035, utilizes a unique mechanism to offer neuroprotection and improve patient quality of life, marking a significant advancement in ALS treatment. Supported by a robust clinical pipeline and a thorough understanding of neurological disease complexities, Amylyx is well-positioned to meet critical unmet medical needs and enhance therapeutic options for ALS and related disorders.